Reaction
Pancreatic Enzymes Increased reporting signals
As of the last recalculation, Pancreatic Enzymes Increased appears in 1,435 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is SORAFENIB (PRR 23.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sorafenib | 33 | 23.6 | 23.6 |
| Teduglutide | 15 | 16.3 | 16.3 |
| Nilotinib | 32 | 16.1 | 16.1 |
| Liraglutide | 44 | 13.3 | 13.3 |
| Durvalumab | 13 | 9.3 | 9.3 |
| Cladribine | 6 | 9.1 | 9.1 |
| Linagliptin | 11 | 8.8 | 8.8 |
| Rifampicin | 6 | 8.6 | 8.6 |
| Ipilimumab | 25 | 8.5 | 8.5 |
| Sitagliptin And Metformin Hydrochloride | 12 | 8.1 | 8.1 |
| Trametinib | 13 | 7.9 | 7.9 |
| Pyrazinamide | 5 | 7.7 | 7.7 |
| Nivolumab | 50 | 7.7 | 7.7 |
| Exenatide | 26 | 7.3 | 7.3 |
| Bosutinib | 4 | 6.5 | 6.5 |
| Tirzepatide | 69 | 6.5 | 6.5 |
| Orlistat | 11 | 6.2 | 6.2 |
| Cabozantinib | 20 | 6.1 | 6.1 |
| Dulaglutide | 34 | 5.7 | 5.7 |
| Dabrafenib | 8 | 5.5 | 5.5 |
| Oral Semaglutide | 27 | 5.4 | 5.4 |
| Vemurafenib | 4 | 4.8 | 4.8 |
| Dasatinib | 10 | 3.9 | 3.9 |